CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision ...
A “Strong Buy” rating from Wall Street indicates that analysts believe a stock has the potential for future price ...
The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback